Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C-Cure
- Development stage
- Phase 3
- Lead developer
- Celyad Oncology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intramyocardial
01
Overview
C-Cure is an autologous cell therapy developed for the treatment of chronic ischemic heart failure. The therapy involves harvesting mesenchymal stem cells (MSCs) from a patient's own bone marrow, which are then exposed to a proprietary 'cardiopoietic cocktail' of growth factors (including TGF-beta, BMP-2, and FGF-2) to induce a cardiopoietic phenotype. These lineage-specified cells are intended to differentiate into functional cardiomyocytes and promote myocardial repair upon delivery. The cells are administered back into the patient's heart via intramyocardial injection using a specialized curved-needle catheter. Developed by Cardio3 BioSciences (now Celyad Oncology), C-Cure reached Phase III clinical testing in the CHART-1 trial. However, the trial failed to meet its primary endpoint in the overall population, leading the developer to discontinue its cardiovascular programs and pivot toward oncology.
- Brand names
- C-Cure
- Other names
- autologous cardiopoietic cellscardiopoietic stem cells
Beyond the preview
Go deeper on C-Cure.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C-Cure.